Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Wall Street slides, ending seesaw week in a risk-off mood

09/17/2021 | 02:34pm EDT

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)

* Nasdaq leads losses as technology majors sink

* S&P 500 trades close to 50-day moving average

* Triple options expiry likely to increase volatility

* Indexes set for weekly losses

* Indexes down: Dow 0.49%, S&P 0.87%, Nasdaq 1.05%

NEW YORK, Sept 17 (Reuters) - Wall Street slid on Friday in a broad sell-off, rounding out a topsy-turvy week in which investors juggled signs of economic strength with concerns over corporate tax increases, stress from the Delta COVID variant, and possible shifts in the U.S. Federal Reserve's timeline for tapering asset purchases.

All three major U.S. stock indexes fell, with the Nasdaq Composite Index suffering the biggest decline as rising U.S. Treasury yields pressured market-leading growth stocks.

They were also on track to post weekly losses, with the S&P index setting a course for its biggest two-week drop since February.

"We're seeing a market where investors are pulling to the sidelines," said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. "It's a market that's being driven by cautiousness rather than any shift in fundamentals."

A potential hike in corporate taxes could eat into earnings also weigh on markets, with leading Democrats seeking to raise the top tax rate on corporations to 26.5% from the current 21%.

While consumer sentiment steadied this month it remains depressed, according to a University of Michigan report, as Americans postpone purchases while inflation remains high.

Inflation is likely to be a major issue next week, when the Federal Open Markets Committee holds its two-day monetary policy meeting. Market participants will be watching closely for changes in nuance which could signal a shift in the Fed's tapering timeline.

"It has been a week of mixed economic data and we are focused clearly on what will come out of the Fed meeting next week," said Bill Northey, senior investment director at U.S. Bank Wealth Management in Helena, Montana.

The Dow Jones Industrial Average fell 170.15 points, or 0.49%, to 34,581.17; the S&P 500 lost 38.97 points, or 0.87%, at 4,434.78; and the Nasdaq Composite dropped 159.70 points, or 1.05%, to 15,022.22.

The S&P 500 dropped close to its 50-day moving average, which in recent history has proven a rather sturdy support level.

Of the 11 major sectors in the S&P 500 materials and technology shares were suffering the biggest percentage drops.

COVID vaccine manufacturers Pfizer Inc and Moderna Inc dropped 1.3% and 4.8%, respectively, as U.S. health officials moved the debate over booster doses to a panel of independent experts.

U.S. Steel Corp shed 8.6% after it unveiled a $3 billion mill investment plan.

Robinhood Markets Inc rose 1.5% after Cathie Wood's ARK Invest bought $14.7 million worth of shares in the trading platform.

Volume and volatility is likely elevated toward the end of the session due to "triple witching," which is the quarterly, simultaneous expiration of stock options, stock index futures, and stock index options contracts.

Declining issues outnumbered advancing ones on the NYSE by a 2.18-to-1 ratio; on Nasdaq, a 1.24-to-1 ratio favored decliners.

The S&P 500 posted seven new 52-week highs and two new lows; the Nasdaq Composite recorded 57 new highs and 60 new lows.

(Reporting by Stephen Culp; Additional reporting by Krystal Hu in New York and Ambar Warrick in Bengaluru; Editing by Richard Chang)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 2.94% 334.05 Delayed Quote.210.34%
ROBINHOOD MARKETS, INC. -1.41% 40.55 Delayed Quote.0.00%
All news about MODERNA, INC.
05:19aASTRAZENECA : EU has exported over 1 bln COVID-19 vaccines, von der Leyen says
RE
10/17MODERNA : U.S. administers 408.3 mln doses of COVID-19 vaccines - CDC
RE
10/16MODERNA : U.S. administers 407.4 mln doses of COVID-19 vaccines -CDC
RE
10/16MODERNA : U.S. CDC Says Administered 407,446,961 Doses Of COVID-19 Vaccine As Of Oct 16
RE
10/15Stocks rise on strong earnings reports
RE
10/15MODERNA : Wall St ends up with Goldman; Dow posts biggest weekly rise since June
RE
10/15JOHNSON & JOHNSON : COVID-19 Vaccine Booster Shot Receives FDA Advisory Panel Recommendati..
MT
10/15MODERNA : NIH's Collins Says FDA Wants to Study Moderna Covid Shot in Kids Longer
MT
10/15MODERNA : U.S. administers 406.6 mln doses of COVID-19 vaccines - CDC
RE
10/15FDA panel recommends J&J COVID-19 booster for all recipients who got first shot
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 335 M - -
Net income 2021 12 514 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 131 B 131 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,07x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 324,21 $
Average target price 299,31 $
Spread / Average Target -7,68%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-39.69%25 414
ALNYLAM PHARMACEUTICALS, INC.60.47%24 787